tetano
Editor, Senior Moderator
Intern Med
. 2025 Jul 3.
doi: 10.2169/internalmedicine.5811-25. Online ahead of print. Coronavirus Disease 2019-associated Minimal Change Disease: Transient Improvement Does Not Preclude the Need for Standard Therapy in a Case Report and Review of the Literature
Ryosuke Saiki[SUP] 1 [/SUP], Kan Katayama[SUP] 1 [/SUP], Enyo Akiyama[SUP] 1 [/SUP], Tomohiro Murata[SUP] 1 [/SUP], Kaoru Dohi[SUP] 1 [/SUP]
Affiliations
Minimal change disease can be associated with coronavirus disease 2019 (COVID-19). We herein report a 38-year-old woman who developed biopsy-proven minimal change disease 5 days after COVID-19 infection. Initial observation showed some spontaneous reduction in proteinuria, which later worsened. Treatment with low-dose prednisolone (0.4 mg/kg/day) led to temporary improvement; however, relapse occurred upon tapering. Complete remission required addition of cyclosporine and rituximab. This case suggests that although COVID-19-associated nephrotic syndrome may initially improve post-infection, standard-dose immunosuppressive therapy may be necessary if complete remission is not achieved.
Keywords: coronavirus disease 2019; minimal change disease; nephrotic syndrome.
. 2025 Jul 3.
doi: 10.2169/internalmedicine.5811-25. Online ahead of print. Coronavirus Disease 2019-associated Minimal Change Disease: Transient Improvement Does Not Preclude the Need for Standard Therapy in a Case Report and Review of the Literature
Ryosuke Saiki[SUP] 1 [/SUP], Kan Katayama[SUP] 1 [/SUP], Enyo Akiyama[SUP] 1 [/SUP], Tomohiro Murata[SUP] 1 [/SUP], Kaoru Dohi[SUP] 1 [/SUP]
Affiliations
- PMID: 40603100
- DOI: 10.2169/internalmedicine.5811-25
Minimal change disease can be associated with coronavirus disease 2019 (COVID-19). We herein report a 38-year-old woman who developed biopsy-proven minimal change disease 5 days after COVID-19 infection. Initial observation showed some spontaneous reduction in proteinuria, which later worsened. Treatment with low-dose prednisolone (0.4 mg/kg/day) led to temporary improvement; however, relapse occurred upon tapering. Complete remission required addition of cyclosporine and rituximab. This case suggests that although COVID-19-associated nephrotic syndrome may initially improve post-infection, standard-dose immunosuppressive therapy may be necessary if complete remission is not achieved.
Keywords: coronavirus disease 2019; minimal change disease; nephrotic syndrome.